Israel-based XTL Biopharmaceuticals has entered into a term sheet to acquire the activity of MinoGuard, also based in Israel, by obtaining an exclusive license to use MinoGuard's entire technology in return for royalties on sales and milestone payments throughout the clinical development process.

MinoGuard commercializes combination therapies for treating psychotic diseases, focusing on schizophrenia. XTL has focused on developing a drug for the treatment of multiple myeloma and hepatitis C. The transaction is subject, among other things, to due diligence studies, examination of the regulatory track for the continued development of the drug and the approval of the company's board.